1. Home
  2. AIDX vs LTRN Comparison

AIDX vs LTRN Comparison

Compare AIDX & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIDX

20/20 Biolabs Inc. Common Stock

N/A

Current Price

$1.60

Market Cap

19.5M

Sector

Health Care

ML Signal

N/A

Logo Lantern Pharma Inc.

LTRN

Lantern Pharma Inc.

HOLD

Current Price

$2.15

Market Cap

22.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIDX
LTRN
Founded
N/A
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.5M
22.2M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
AIDX
LTRN
Price
$1.60
$2.15
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
56.6K
315.7K
Earning Date
N/A
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
18.65
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.45
$1.11
52 Week High
$14.09
$5.74

Technical Indicators

Market Signals
Indicator
AIDX
LTRN
Relative Strength Index (RSI) 22.69 45.48
Support Level $1.51 $1.11
Resistance Level $2.08 $2.41
Average True Range (ATR) 0.13 0.32
MACD 0.10 -0.03
Stochastic Oscillator 25.00 15.12

Price Performance

Historical Comparison
AIDX
LTRN

About AIDX 20/20 Biolabs Inc. Common Stock

20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.

Share on Social Networks: